Cirrhosis of liver

Summary

Cirrhosis of liver (MONDO:0005155) is a disease with 30 cohort genes (111 GWAS associations across 35 studies) and 542 clinical trials. Top therapeutic interventions include propranolol, albumin human, and carvedilol.

At a glance

• Cohort genes: 30
• GWAS associations: 111
• ClinVar variants: 5
• Clinical trials: 542

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cirrhosis of liver
Mondo ID	MONDO:0005155
EFO	EFO:0001422
MeSH	D008103
DOID	DOID:5082
NCIT	C2951
SNOMED CT	19943007
UMLS	C0023890
MedGen	7368
Is cancer (heuristic)	no

Also known as: cirrhosis

Data availability: 5 ClinVar variants · 111 GWAS associations (35 studies) · 18 cell lines.

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › cirrhosis of liver

Related subtypes (31): polycystic echinococcosis, autosomal dominant polycystic liver disease, hepatorenal syndrome, hepatitis, hepatic vascular disorder, hepatic porphyria, hepatopulmonary syndrome, fatty liver disease, drug-induced liver injury, perinatal jaundice due to hepatocellular damage, Aagenaes syndrome, transient familial neonatal hyperbilirubinemia, hyperbiliverdinemia, transient infantile hypertriglyceridemia and hepatosteatosis, idiopathic copper-associated cirrhosis, familial intrahepatic cholestasis, bile duct cyst, nodular regenerative hyperplasia of the liver, hepatoportal sclerosis, primitive portal vein thrombosis, glycogen storage disease due to liver phosphorylase kinase deficiency, liver and intrahepatic bile duct neoplasm, alcoholic liver disease, early-onset familial noncirrhotic portal hypertension, liver failure, fibrotic liver disease, intestinal failure–associated liver disease, liver abscess (disease), membranous obstruction of inferior vena cava, liver disease, severe congenital, cystic fibrosis-related liver disease

Subtypes (3): hepatitis C induced liver cirrhosis, alcoholic liver cirrhosis, cirrhosis, familial

Genetics & variants

GWAS landscape

111 GWAS associations across 35 studies. Top hits map to 29 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs738409	2e-290	PNPLA3	G
rs738408	1e-270	PNPLA3	T	0.46
rs58542926	3e-83	TM6SF2	T
rs28929474	8e-56	SERPINA1	T
rs6834314	3e-54	KLHL8 - MIR5705	G
rs739846	3e-47	SUGP1	A	0.3
rs2642438	1e-43	MTARC1	A
rs13056638	9e-34	PNPLA3	?
rs28636836	2e-29	HSD17B13	T	0.14
rs4803221	1e-25	IFNL4	C	0.13
rs112635299	1e-24	SERPINA2 - SERPINA1	G	0.4
rs2642439	6e-22	MTARC1	A	0.12
rs2896019	2e-20	PNPLA3	G	2.02
rs28746951	4e-18	HLA-DQB1 - MTCO3P1	G	0.12
rs3747207	3e-17	PNPLA3	G	0.25
rs671	1e-16	ALDH2	A	0.28
rs11735092	2e-16	HSD17B13	T	0.1
rs2001846	9e-16	TRIB1 - TRIB1AL	T	0.09
rs483082	3e-14	APOE - APOC1	T	0.1
chr9:5073770	4e-14		T	9.59
rs5117	6e-14	APOC1	T	0.1
rs73004962	3e-13	PBX4	?	1.28
rs78069066	1e-12	MAPKAPK5, ADAM1A	A	0.76
rs12484700	1e-12	PNPLA3	G	1.24
rs6982502	2e-12	TRIB1AL	C	0.09
rs59325138	1e-11	APOE - APOC1	C	0.09
rs3129943	2e-11	TSBP1-AS1, TSBP1	G	0.2
rs200663261	2e-11	TSBP1-AS1	CTACA	0.19
rs80215559	5e-11	SLC17A2	?	1.47
rs4374383	1e-09	MERTK	A

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90432139	Jiang Y	2023	116,382	213,325	A cross-disorder study to identify causal relationships, shared genetic variants, and genes across 21 digestive disorders.
GCST90319877	Ghouse J	2024	15,225	1,564,786	Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis.
GCST90319878	Ghouse J	2024	15,225	1,564,786	Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis.
GCST90476086	Verma A	2024	13,367	433,864	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478453	Verma A	2024	5,063	115,171	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480337	Verma A	2024	5,063	115,171	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651162	Liu TY	2025	3,794	217,650	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90476085	Verma A	2024	2,679	56,567	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90018606	Sakaue S	2021	2,551	176,175	A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90013710	Ishigaki K	2020	2,184	210,269	Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	6
Tier 2: splice/UTR	6
Tier 3: regulatory	1
Tier 4: intronic/intergenic	37

MAF distribution

Bucket	Variants
common (>=0.05)	46
low_freq (0.01-0.05)	2
rare (<0.01)	0
unknown	2

Functional consequences

Consequence	Count
intron_variant	26
intergenic_variant	7
missense_variant	5
3_prime_UTR_variant	5
non_coding_transcript_exon_variant	2
synonymous_variant	1
stop_gained	1
unknown	1
regulatory_region_variant	1
splice_donor_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs738409	22	43928847	C>A,G,T	0.23	missense_variant	PNPLA3	2e-290	Tier 1: coding
rs738408	22	43928850	C>A,G,T	0.05	synonymous_variant	PNPLA3	1e-270	Tier 4: intronic/intergenic
rs58542926	19	19268740	C>A,T	0.07	stop_gained	TM6SF2	3e-83	Tier 1: coding
rs28929474	14	94378610	C>A,G,T	0.02	missense_variant	SERPINA1	8e-56	Tier 1: coding
rs6834314	4	87292656	A>G	0.26	intergenic_variant	KLHL8 - MIR5705	3e-54	Tier 4: intronic/intergenic
rs739846	19	19308262	G>A	0.05	intron_variant	SUGP1	3e-47	Tier 4: intronic/intergenic
rs2642438	1	220796686	A>C,G,T	0.29	missense_variant	MTARC1	1e-43	Tier 1: coding
rs13056638	22	43935898	C>A,G,T	0.05	intron_variant	PNPLA3	9e-34	Tier 4: intronic/intergenic
rs28636836	4	87310713	C>T	0.05	intron_variant	HSD17B13	2e-29	Tier 4: intronic/intergenic
rs4803221	19	39248489	C>G,T	0.209	missense_variant	IFNL4	1e-25	Tier 1: coding
rs112635299	14	94371805	G>A,C,T	0.014	intron_variant	SERPINA2 - SERPINA1	1e-24	Tier 4: intronic/intergenic
rs2642439	1	220797157	A>C,G,T	0.05	intron_variant	MTARC1	6e-22	Tier 4: intronic/intergenic
rs2896019	22	43937814	T>G	0.45	intron_variant	PNPLA3	2e-20	Tier 4: intronic/intergenic
rs28746951	6	32685018	G>A,C	0.224	intergenic_variant	HLA-DQB1 - MTCO3P1	4e-18	Tier 4: intronic/intergenic
rs3747207	22	43928975	G>A,C,T	0.406	intron_variant	PNPLA3	3e-17	Tier 4: intronic/intergenic
rs671	12	111803962	G>A	0.247	missense_variant	ALDH2	1e-16	Tier 1: coding
rs11735092	4	87305079	T>C	0.426	3_prime_UTR_variant	HSD17B13	2e-16	Tier 2: splice/UTR
rs2001846	8	125466208	T>A,C,G	0.428	intergenic_variant	TRIB1 - TRIB1AL	9e-16	Tier 4: intronic/intergenic
rs483082	19	44912921	G>T	0.05	non_coding_transcript_exon_variant	APOE - APOC1	3e-14	Tier 4: intronic/intergenic
chr9:5073770							4e-14	Tier 4: intronic/intergenic
rs5117	19	44915533	T>A,C,G	0.223	intron_variant	APOC1	6e-14	Tier 4: intronic/intergenic
rs73004962	19	19602260	A>C,T	0.05	intron_variant	PBX4	3e-13	Tier 4: intronic/intergenic
rs78069066	12	111900120	G>A	0.231	3_prime_UTR_variant	MAPKAPK5, ADAM1A	1e-12	Tier 2: splice/UTR
rs12484700	22	43931393	A>C,G	0.454	intron_variant	PNPLA3	1e-12	Tier 4: intronic/intergenic
rs6982502	8	125467120	C>T	0.491	intron_variant	TRIB1AL	2e-12	Tier 4: intronic/intergenic
rs59325138	19	44913034	C>G,T	0.389	non_coding_transcript_exon_variant	APOE - APOC1	1e-11	Tier 4: intronic/intergenic
rs3129943	6	32370918	A>G	0.365	intron_variant	TSBP1-AS1, TSBP1	2e-11	Tier 4: intronic/intergenic
rs200663261	6	32276304	CTACA>C,CTACATACA,CTACATACATACA,CTACATACATACATACA,CTACATACATACATACATACA,CTACATACATACATACATACATACA	0.05	intron_variant	TSBP1-AS1	2e-11	Tier 4: intronic/intergenic
rs80215559	6	25917997	T>C	0.05	intron_variant	SLC17A2	5e-11	Tier 4: intronic/intergenic
rs4374383	2	112013193	A>G	0.42	intron_variant	MERTK	1e-09	Tier 4: intronic/intergenic

ClinVar germline variants

5 retrieved; paginated sample, class counts are floors:

5 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
545642	NM_005687.5(FARSB):c.1381A>C (p.Thr461Pro)	FARSB	Pathogenic	criteria provided, single submitter
545655	NM_005687.5(FARSB):c.784A>G (p.Lys262Glu)	FARSB	Pathogenic	criteria provided, single submitter
545664	NM_005687.5(FARSB):c.1202G>A (p.Arg401Gln)	FARSB	Pathogenic	criteria provided, single submitter
545694	NM_005687.5(FARSB):c.755T>C (p.Phe252Ser)	FARSB	Pathogenic	no assertion criteria provided
545695	NM_005687.5(FARSB):c.226T>C (p.Cys76Arg)	FARSB	Pathogenic	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 19 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TULP1	Orphanet:65	Leber congenital amaurosis
TULP1	Orphanet:791	Retinitis pigmentosa
CACNA2D1	Orphanet:130	Brugada syndrome
CACNA2D1	Orphanet:442835	Non-specific early-onset epileptic encephalopathy
CACNA2D1	Orphanet:51083	Congenital short QT syndrome
PALLD	Orphanet:1333	Familial pancreatic carcinoma
FARSB	Orphanet:178506	Interstitial lung disease-brain calcification syndrome
PKD1L1	Orphanet:101063	Situs inversus totalis
PKD1L1	Orphanet:157769	Situs ambiguus
COL13A1	Orphanet:98913	Postsynaptic congenital myasthenic syndrome
COL13A1	Orphanet:98914	Presynaptic congenital myasthenic syndromes
LTBP2	Orphanet:238763	Glaucoma secondary to spherophakia/ectopia lentis and megalocornea
LTBP2	Orphanet:3449	Weill-Marchesani syndrome
LTBP2	Orphanet:98976	Congenital glaucoma
MERTK	Orphanet:791	Retinitis pigmentosa
NGF	Orphanet:64752	Hereditary sensory and autonomic neuropathy type 5
SERPINA1	Orphanet:178396	Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation
SERPINA1	Orphanet:586	Cystic fibrosis
SERPINA1	Orphanet:60	Alpha-1-antitrypsin deficiency

Cohort genes → proteins

30 cohort genes, 30 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	29
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
RNF7	HGNC:10070	ENSG00000114125	Q9UBF6	RING-box protein 2	gwas
ST8SIA1	HGNC:10869	ENSG00000111728	Q92185	Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase	gwas
TM6SF2	HGNC:11861	ENSG00000213996	Q9BZW4	Transmembrane 6 superfamily member 2	gwas
TULP1	HGNC:12423	ENSG00000112041	O00294	Tubby-related protein 1	gwas
CACNA2D1	HGNC:1399	ENSG00000153956	P54289	Voltage-dependent calcium channel subunit alpha-2/delta-1	gwas
PARVB	HGNC:14653	ENSG00000188677	Q9HBI1	Beta-parvin	gwas
ZP4	HGNC:15770	ENSG00000116996	Q12836	Zona pellucida sperm-binding protein 4	gwas
MACROD2	HGNC:16126	ENSG00000172264	A1Z1Q3	ADP-ribose glycohydrolase MACROD2	gwas
PALLD	HGNC:17068	ENSG00000129116	Q8WX93	Palladin	gwas
FARSB	HGNC:17800	ENSG00000116120	Q9NSD9	Phenylalanine–tRNA ligase beta subunit	clinvar
PKD1L1	HGNC:18053	ENSG00000158683	Q8TDX9	Polycystin-1-like protein 1	gwas
PNPLA3	HGNC:18590	ENSG00000100344	Q9NST1	1-acylglycerol-3-phosphate O-acyltransferase PNPLA3	gwas
HSD17B13	HGNC:18685	ENSG00000170509	Q7Z5P4	17-beta-hydroxysteroid dehydrogenase 13	gwas
COL13A1	HGNC:2190	ENSG00000197467	Q5TAT6	Collagen alpha-1(XIII) chain	gwas
SAMM50	HGNC:24276	ENSG00000100347	Q9Y512	Sorting and assembly machinery component 50 homolog	gwas
GLT8D2	HGNC:24890	ENSG00000120820	Q9H1C3	Glycosyltransferase 8 domain-containing protein 2	gwas
MTARC1	HGNC:26189	ENSG00000186205	Q5VT66	Mitochondrial amidoxime-reducing component 1	gwas
DDX60L	HGNC:26429	ENSG00000181381	Q5H9U9	Probable ATP-dependent RNA helicase DDX60-like	gwas
DCLK1	HGNC:2700	ENSG00000133083	O15075	Serine/threonine-protein kinase DCLK1	gwas
CRACR2A	HGNC:28657	ENSG00000130038	Q9BSW2	EF-hand calcium-binding domain-containing protein 4B	gwas
EHBP1L1	HGNC:30682	ENSG00000173442	Q8N3D4	EH domain-binding protein 1-like protein 1	gwas
TEX36	HGNC:31653	ENSG00000175018	Q5VZQ5	Testis-expressed protein 36	gwas
FARP1	HGNC:3591	ENSG00000152767	Q9Y4F1	FERM, ARHGEF and pleckstrin domain-containing protein 1	gwas
FDFT1	HGNC:3629	ENSG00000079459	P37268	Squalene synthase	gwas
LTBP2	HGNC:6715	ENSG00000119681	Q14767	Latent-transforming growth factor beta-binding protein 2	gwas
MERTK	HGNC:7027	ENSG00000153208	Q12866	Tyrosine-protein kinase Mer	gwas
NGF	HGNC:7808	ENSG00000134259	P01138	Beta-nerve growth factor	gwas
SERPINA1	HGNC:8941	ENSG00000197249	P01009	Alpha-1-antitrypsin	gwas
PTPRU	HGNC:9683	ENSG00000060656	Q92729	Receptor-type tyrosine-protein phosphatase U	gwas
PZP	HGNC:9750	ENSG00000126838	P20742	Pregnancy zone protein	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
RNF7	RING-box protein 2	Catalytic component of multiple cullin-5-RING E3 ubiquitin-protein ligase complexes (ECS complexes), which mediate the ubiquitination and subsequent proteasomal degradation of target proteins.
ST8SIA1	Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase	Catalyzes the addition of sialic acid in alpha 2,8-linkage to the sialic acid moiety of the ganglioside GM3 to form ganglioside GD3; gangliosides are a subfamily of complex glycosphingolipds that contain one or more residues of sialic acid.
TM6SF2	Transmembrane 6 superfamily member 2	Regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.
TULP1	Tubby-related protein 1	Required for normal development of photoreceptor synapses.
CACNA2D1	Voltage-dependent calcium channel subunit alpha-2/delta-1	The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel.
PARVB	Beta-parvin	Adapter protein that plays a role in integrin signaling via ILK and in activation of the GTPases CDC42 and RAC1 by guanine exchange factors, such as ARHGEF6.
ZP4	Zona pellucida sperm-binding protein 4	Component of the zona pellucida, an extracellular matrix surrounding oocytes which mediates sperm binding, induction of the acrosome reaction and prevents post-fertilization polyspermy.
MACROD2	ADP-ribose glycohydrolase MACROD2	Removes ADP-ribose from aspartate and glutamate residues in proteins bearing a single ADP-ribose moiety.
PALLD	Palladin	Cytoskeletal protein required for organization of normal actin cytoskeleton.
PKD1L1	Polycystin-1-like protein 1	Component of a calcium-permeant ion channel formed by PKD1L2 and PKD1L1 in primary cilia, where it controls cilium calcium concentration, without affecting cytoplasmic calcium concentration, and regulates sonic hedgehog/SHH signaling and G…
PNPLA3	1-acylglycerol-3-phosphate O-acyltransferase PNPLA3	Specifically catalyzes coenzyme A (CoA)-dependent acylation of 1-acyl-sn-glycerol 3-phosphate (2-lysophosphatidic acid/LPA) to generate phosphatidic acid (PA), an important metabolic intermediate and precursor for both triglycerides and gl…
HSD17B13	17-beta-hydroxysteroid dehydrogenase 13	Plays a pivotal role in hepatic lipid metabolism.
COL13A1	Collagen alpha-1(XIII) chain	Involved in cell-matrix and cell-cell adhesion interactions that are required for normal development.
SAMM50	Sorting and assembly machinery component 50 homolog	Plays a crucial role in the maintenance of the structure of mitochondrial cristae and the proper assembly of the mitochondrial respiratory chain complexes.
MTARC1	Mitochondrial amidoxime-reducing component 1	Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles.
DCLK1	Serine/threonine-protein kinase DCLK1	Probable kinase that may be involved in a calcium-signaling pathway controlling neuronal migration in the developing brain.
CRACR2A	EF-hand calcium-binding domain-containing protein 4B	Ca(2+)-binding protein that plays a key role in store-operated Ca(2+) entry (SOCE) in T-cells by regulating CRAC channel activation.
EHBP1L1	EH domain-binding protein 1-like protein 1	May act as Rab effector protein and play a role in vesicle trafficking.
FARP1	FERM, ARHGEF and pleckstrin domain-containing protein 1	Functions as a guanine nucleotide exchange factor for RAC1.
FDFT1	Squalene synthase	Catalyzes the condensation of 2 farnesyl pyrophosphate (FPP) moieties to form squalene.
LTBP2	Latent-transforming growth factor beta-binding protein 2	May play an integral structural role in elastic-fiber architectural organization and/or assembly.
MERTK	Tyrosine-protein kinase Mer	Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6.
NGF	Beta-nerve growth factor	Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems.
SERPINA1	Alpha-1-antitrypsin	Inhibitor of serine proteases.
PTPRU	Receptor-type tyrosine-protein phosphatase U	Tyrosine-protein phosphatase which dephosphorylates CTNNB1.
PZP	Pregnancy zone protein	Is able to inhibit all four classes of proteinases by a unique ’trapping’ mechanism.

Protein-family classification

Druggable: 12 · Difficult: 2 · Unknown: 16 · Druggable fraction: 0.4

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Complement	1	8.9×	0.283
Antibody/Immunoglobulin	3	2.9×	0.283
Enzyme (other)	5	2.0×	0.283
Phosphatase	1	2.8×	0.484
Kinase	2	1.9×	0.484
Other/Unknown	16	1.0×	0.904
Scaffold/PPI	1	0.6×	0.952
Transcription factor	1	0.3×	0.979

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
RNF7	Transcription factor	no		Znf_RING, Znf_RING/FYVE/PHD, Znf_RING_H2
ST8SIA1	Enzyme (other)	yes	2.4.99.8	Glyco_trans_29, Sialyl_trans, GT29-like_sf
TM6SF2	Other/Unknown	no		EXPERA, TM6SF1-like, TM_Tm6sf1/2
TULP1	Other/Unknown	no		Tubby_C, Tubby_C_CS, Tubby-like_C
CACNA2D1	Other/Unknown	no		VWF_A, VWA_N, VDCC_a2/dsu
PARVB	Other/Unknown	no		CH_dom, Parvin, CH_dom_sf
ZP4	Antibody/Immunoglobulin	yes		P_trefoil_dom, ZP_dom, P_trefoil_CS
MACROD2	Enzyme (other)	yes	3.1.1.106	Macro_dom, Macro_dom-like
PALLD	Antibody/Immunoglobulin	yes		Ig_sub2, Ig_sub, Ig-like_dom
FARSB	Enzyme (other)	yes	6.1.1.20	Phe-tRNA-synth_IIc_bsu_arc_euk, B3/B4_tRNA-bd, tRNA_synthase_B5-dom
PKD1L1	Antibody/Immunoglobulin	yes		PKD_dom, PLAT/LH2_dom, PKD/REJ-like
PNPLA3	Other/Unknown	no		PNPLA_dom, Acyl_Trfase/lysoPLipase, PLPL
HSD17B13	Other/Unknown	no		SDR_fam, NAD(P)-bd_dom_sf
COL13A1	Other/Unknown	no		Collagen, Collagen_Structural_Proteins
SAMM50	Other/Unknown	no		Bac_surfAg_D15, POTRA, D15-like
GLT8D2	Other/Unknown	no		Glyco_trans_8, Nucleotide-diphossugar_trans, Glycosyltrans_8_dom-fam
MTARC1	Enzyme (other)	yes	1.16.98.B1	MoCF_Sase_C, MOCOS_middle, Pyrv_Knase-like_insert_dom_sf
DDX60L	Other/Unknown	no		Helicase_C-like, DEAD/DEAH_box_helicase_dom, Helicase_ATP-bd
DCLK1	Kinase	yes	2.7.11.1	Prot_kinase_dom, Doublecortin_dom, Ser/Thr_kinase_AS
CRACR2A	Other/Unknown	no		Small_GTPase, EF_hand_dom, Small_GTP-bd
EHBP1L1	Other/Unknown	no		CH_dom, NT-C2, bMERB_dom
TEX36	Other/Unknown	no		HDNR
FARP1	Scaffold/PPI	no		DH_dom, FERM_domain, Ez/rad/moesin-like
FDFT1	Enzyme (other)	yes	2.5.1.21	Squ/phyt_synthse, Squal_synth-like, Isoprenoid_synthase_dom_sf
LTBP2	Other/Unknown	no		EGF-type_Asp/Asn_hydroxyl_site, EGF, EGF-like_Ca-bd_dom
MERTK	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Ig_sub
NGF	Other/Unknown	no		Nerve_growth_factor-rel, Nerve_growth_factor_CS, Nerve_growth_factor-like
SERPINA1	Other/Unknown	no		Serpin_fam, Serpin_CS, Serpin_dom
PTPRU	Phosphatase	yes	3.1.3.48	PTP_cat, Tyr_Pase_dom, MAM_dom
PZP	Complement	yes		Macroglobln_a2, MG2, Terpenoid_cyclase/PrenylTrfase

Expression context

Cohort genes with no expression data: 0.

29 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	1
broad (>20)	29
unknown	0

Top tissues across cohort

Tissue	Cohort genes
endothelial cell	3
right lobe of liver	3
right adrenal gland	2
cortical plate	2
ganglionic eminence	2
ileal mucosa	2
jejunal mucosa	2
primordial germ cell in gonad	2
skeletal muscle tissue of rectus abdominis	2
buccal mucosa cell	2
liver	2
olfactory segment of nasal mucosa	2
descending thoracic aorta	2
adrenal tissue	2
left adrenal gland	1
left adrenal gland cortex	1
ventricular zone	1
duodenum	1
retina	1
tendon of biceps brachii	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
RNF7	292	ubiquitous	marker	left adrenal gland, left adrenal gland cortex, right adrenal gland
ST8SIA1	224	broad	marker	ventricular zone, ganglionic eminence, cortical plate
TM6SF2	151	broad	marker	ileal mucosa, jejunal mucosa, duodenum
TULP1	134	tissue_specific	marker	primordial germ cell in gonad, tendon of biceps brachii, retina
CACNA2D1	261	ubiquitous	marker	biceps brachii, skeletal muscle tissue of biceps brachii, skeletal muscle tissue of rectus abdominis
PARVB	235	ubiquitous	marker	hindlimb stylopod muscle, gastrocnemius, muscle of leg
ZP4	18		marker	oocyte, secondary oocyte, pancreatic ductal cell
MACROD2	214	ubiquitous	marker	endothelial cell, buccal mucosa cell, epithelial cell of pancreas
PALLD	302	ubiquitous	marker	saphenous vein, heart right ventricle, blood vessel layer
FARSB	264	ubiquitous	marker	left ventricle myocardium, cardiac muscle of right atrium, gingival epithelium
PKD1L1	150	tissue_specific	marker	male germ line stem cell (sensu Vertebrata) in testis, apex of heart, primordial germ cell in gonad
PNPLA3	178	ubiquitous	marker	pigmented layer of retina, buccal mucosa cell, right lobe of liver
HSD17B13	127	tissue_specific	yes	liver, right lobe of liver, olfactory segment of nasal mucosa
COL13A1	209	ubiquitous	marker	cerebellar hemisphere, cerebellar cortex, cerebellum
SAMM50	292	ubiquitous	marker	endothelial cell, vastus lateralis, skeletal muscle tissue of rectus abdominis
GLT8D2	247	ubiquitous	marker	tibia, parietal pleura, descending thoracic aorta
MTARC1	209	ubiquitous	marker	adipose tissue, adipose tissue of abdominal region, omental fat pad
DDX60L	229	ubiquitous	marker	monocyte, leukocyte, jejunal mucosa
DCLK1	264	ubiquitous	marker	endothelial cell, frontal pole, cortical plate
CRACR2A	210	broad	marker	parotid gland, ileal mucosa, mucosa of sigmoid colon
EHBP1L1	233	ubiquitous	marker	granulocyte, lower esophagus, lower esophagus muscularis layer
TEX36	30	tissue_specific	marker	left testis, right testis, testis
FARP1	283	ubiquitous	marker	renal medulla, stromal cell of endometrium, adrenal tissue
FDFT1	236	ubiquitous	marker	embryo, ganglionic eminence, adrenal tissue
LTBP2	276	ubiquitous	marker	descending thoracic aorta, thoracic aorta, ascending aorta
MERTK	246	ubiquitous	marker	right adrenal gland cortex, mucosa of stomach, right adrenal gland
NGF	158	broad	marker	cartilage tissue, left uterine tube, right ovary
SERPINA1	133	ubiquitous	marker	right lobe of liver, liver, blood
PTPRU	239	ubiquitous	marker	endocervix, olfactory segment of nasal mucosa, ectocervix
PZP	178	tissue_specific	marker	bronchial epithelial cell, epithelium of bronchus, bronchus

Protein interactions among cohort

Intra-cohort edges: 12.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
NGF	3,968
SERPINA1	3,617
DCLK1	3,597
HSD17B13	3,393
FARSB	3,392
FDFT1	3,249
SAMM50	2,977
MERTK	2,735
LTBP2	2,658
RNF7	2,453

Intra-cohort edges

A	B	Sources
CACNA2D1	GLT8D2	biogrid_interaction
FDFT1	PNPLA3	string_interaction
FDFT1	TM6SF2	string_interaction
HSD17B13	MTARC1	string_interaction
HSD17B13	PNPLA3	string_interaction
HSD17B13	SAMM50	string_interaction
HSD17B13	TM6SF2	string_interaction
MERTK	TULP1	string_interaction
MTARC1	PNPLA3	string_interaction
MTARC1	TM6SF2	string_interaction
PNPLA3	SAMM50	string_interaction
PNPLA3	TM6SF2	string_interaction

Structural data

PDB: 18 · AlphaFold-only: 12 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
SERPINA1	P01009	46
MERTK	Q12866	42
FDFT1	P37268	32
CACNA2D1	P54289	30
DCLK1	O15075	11
NGF	P01138	10
RNF7	Q9UBF6	7
MACROD2	A1Z1Q3	4
PARVB	Q9HBI1	3
FARSB	Q9NSD9	3
MTARC1	Q5VT66	3
TULP1	O00294	2
PALLD	Q8WX93	2
SAMM50	Q9Y512	2
PTPRU	Q92729	2
HSD17B13	Q7Z5P4	1
CRACR2A	Q9BSW2	1
FARP1	Q9Y4F1	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
TM6SF2	Q9BZW4	91.03
ST8SIA1	Q92185	88.71
GLT8D2	Q9H1C3	88.41
PZP	P20742	81.87
DDX60L	Q5H9U9	79.77
ZP4	Q12836	74.90
PNPLA3	Q9NST1	71.70
TEX36	Q5VZQ5	60.88
LTBP2	Q14767	58.33
COL13A1	Q5TAT6	55.67
EHBP1L1	Q8N3D4	49.98
PKD1L1	Q8TDX9

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 87. Enrichment computed across 30 evidence-associated genes (19 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 19 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
TRKA activation by NGF	1	300.5×	0.078	NGF
NFG and proNGF binds to p75NTR	1	300.5×	0.078	NGF
PLC-gamma1 signalling	1	200.3×	0.078	NGF
Ceramide signalling	1	200.3×	0.078	NGF
Signalling to STAT3	1	200.3×	0.078	NGF
NGF processing	1	150.3×	0.078	NGF
Axonal growth stimulation	1	150.3×	0.078	NGF
Signalling to p38 via RIT and RIN	1	120.2×	0.078	NGF
p75NTR negatively regulates cell cycle via SC1	1	100.2×	0.078	NGF
NADE modulates death signalling	1	100.2×	0.078	NGF
Lipid particle organization	1	100.2×	0.078	HSD17B13
Acyl chain remodeling of DAG and TAG	1	85.9×	0.078	PNPLA3
ARMS-mediated activation	1	85.9×	0.078	NGF
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components	1	75.1×	0.082	PARVB
PI3K/AKT activation	1	66.8×	0.086	NGF
Interaction With Cumulus Cells And The Zona Pellucida	1	54.6×	0.097	ZP4
Frs2-mediated activation	1	50.1×	0.097	NGF
p75NTR recruits signalling complexes	1	46.2×	0.097	NGF
NF-kB is activated and signals survival	1	46.2×	0.097	NGF
Retrograde neurotrophin signalling	1	42.9×	0.097	NGF
Lanosterol biosynthesis	1	40.1×	0.097	FDFT1
NRIF signals cell death from the nucleus	1	37.6×	0.097	NGF
Signalling to RAS	1	35.4×	0.097	NGF
Cell-extracellular matrix interactions	1	35.4×	0.097	PARVB
Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	1	35.4×	0.097	CACNA2D1
Asparagine N-linked glycosylation	2	6.3×	0.131	ST8SIA1, SERPINA1
Cytosolic tRNA aminoacylation	1	23.1×	0.132	FARSB
Inactivation of CSF3 (G-CSF) signaling	1	23.1×	0.132	RNF7
Cristae formation	1	18.2×	0.149	SAMM50
Elastic fibre formation	1	17.7×	0.149	LTBP2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 27 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
triglyceride acyl-chain remodeling	1	624.1×	0.043	PNPLA3
farnesyl diphosphate metabolic process	1	624.1×	0.043	FDFT1
detoxification of nitrogen compound	1	312.1×	0.043	MTARC1
cellular response to 3,3’,5-triiodo-L-thyronine	1	312.1×	0.043	PNPLA3
negative regulation of leukocyte apoptotic process	1	312.1×	0.043	MERTK
detection of nodal flow	1	208.1×	0.043	PKD1L1
positive regulation of neuron maturation	1	208.1×	0.043	NGF
nitrate metabolic process	1	208.1×	0.043	MTARC1
purine nucleoside metabolic process	1	208.1×	0.043	MACROD2
negative regulation of lymphocyte activation	1	208.1×	0.043	MERTK
calcium ion transmembrane transport via high voltage-gated calcium channel	1	208.1×	0.043	CACNA2D1
membrane depolarization during bundle of His cell action potential	1	208.1×	0.043	CACNA2D1
regulation of membrane repolarization during action potential	1	208.1×	0.043	CACNA2D1
retrograde trans-synaptic signaling by trans-synaptic protein complex	1	208.1×	0.043	FARP1
peptidyl-glutamate ADP-deribosylation	1	208.1×	0.043	MACROD2
positive regulation of humoral immune response	1	156.0×	0.043	ZP4
phenylalanyl-tRNA aminoacylation	1	156.0×	0.043	FARSB
response to histamine	1	156.0×	0.043	CRACR2A
acylglycerol acyl-chain remodeling	1	156.0×	0.043	PNPLA3
establishment or maintenance of cell polarity regulating cell shape	1	156.0×	0.043	PARVB
negative regulation of focal adhesion disassembly	1	156.0×	0.043	RNF7
negative regulation of binding of sperm to zona pellucida	1	156.0×	0.043	ZP4
axon extension	2	36.7×	0.043	DCLK1, NGF
substrate adhesion-dependent cell spreading	2	25.5×	0.043	PARVB, MERTK
lipid homeostasis	2	25.0×	0.043	TM6SF2, PNPLA3
positive regulation of phagocytosis	2	23.6×	0.043	TULP1, MERTK
retina development in camera-type eye	2	18.9×	0.043	TULP1, MERTK
endosomal transport	2	18.1×	0.043	DCLK1, CRACR2A
response to sucrose	1	124.8×	0.047	PNPLA3
activation of store-operated calcium channel activity	1	124.8×	0.047	CRACR2A

Therapeutics

Drugs indicated for this disease

6 approved, 29 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Ethacrynic Acid	Approved (phase 4)
Furosemide	Approved (phase 4)
Hydrochlorothiazide	Approved (phase 4)
Ribavirin	Approved (phase 4)
Spironolactone	Approved (phase 4)
Triamterene	Approved (phase 4)
Albumin Human	Phase 3 (in late-stage trials)
Bemiparin	Phase 3 (in late-stage trials)
Calcium Carbonate	Phase 3 (in late-stage trials)
Cyclobenzaprine	Phase 3 (in late-stage trials)
Dexamethasone	Phase 3 (in late-stage trials)
Filgrastim	Phase 3 (in late-stage trials)
Fospropofol	Phase 3 (in late-stage trials)
Gabapentin	Phase 3 (in late-stage trials)
Hydrocortisone	Phase 3 (in late-stage trials)
Hydronidone	Phase 3 (in late-stage trials)
INTERFERON ALFA-2B	Phase 3 (in late-stage trials)
Lamivudine	Phase 3 (in late-stage trials)
Methocarbamol	Phase 3 (in late-stage trials)
Midazolam	Phase 3 (in late-stage trials)
Norfloxacin	Phase 3 (in late-stage trials)
PEGINTERFERON ALFA-2A	Phase 3 (in late-stage trials)
PEGINTERFERON ALFA-2B	Phase 3 (in late-stage trials)
Pentoxifylline	Phase 3 (in late-stage trials)
Propofol	Phase 3 (in late-stage trials)
Propranolol	Phase 3 (in late-stage trials)
Rifaximin	Phase 3 (in late-stage trials)
Rivaroxaban	Phase 3 (in late-stage trials)
Satavaptan	Phase 3 (in late-stage trials)
Simvastatin	Phase 3 (in late-stage trials)
Sodium Chloride	Phase 3 (in late-stage trials)
Telbivudine	Phase 3 (in late-stage trials)
Terlipressin	Phase 3 (in late-stage trials)
Tolvaptan	Phase 3 (in late-stage trials)
Vitamin E	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alcohol, Allopurinol, Apixaban, Atorvastatin, Bosentan, Conivaptan, Dapagliflozin, Edoxaban, Enoxaparin Sodium, Epigalocatechin Gallate, Hepatitis B Virus Hbsag Surface Protein Antigen, INTERFERON GAMMA-1B, Icomidocholic Acid, Imiquimod, Lactulose, Oltipraz, Sapropterin, Somatropin, Warfarin, Zibotentan.

Drug target analysis

Approved (phase 4): 4 · Phase ≥3: 5 · Phased (≥1): 6 · Undrugged: 24

Druggability breadth: 12 of 30 evidence-associated genes (40%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CACNA2D1	PREGABALIN
DCLK1	FEDRATINIB
FDFT1	AMIODARONE
MERTK	FEDRATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MERTK	48	4
DCLK1	15	4
CACNA2D1	5	4
FARSB	3	2
FDFT1	3	4
HSD17B13	1	3
RNF7	0	0
ST8SIA1	0	0
TM6SF2	0	0
TULP1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PREGABALIN	4	CACNA2D1
GABAPENTIN	4	CACNA2D1
NIMODIPINE	4	CACNA2D1
TACRINE	4	CACNA2D1
FEDRATINIB	4	DCLK1, MERTK
RUXOLITINIB	4	DCLK1
TOFACITINIB CITRATE	4	DCLK1
TOFACITINIB	4	DCLK1
NINTEDANIB	4	DCLK1, MERTK
SUNITINIB	4	DCLK1, MERTK
CRIZOTINIB	4	DCLK1, MERTK
AMIODARONE	4	FDFT1
AXITINIB	4	MERTK
SORAFENIB	4	MERTK
NERATINIB	4	MERTK
CABOZANTINIB	4	MERTK
VANDETANIB	4	MERTK
BOSUTINIB	4	MERTK
FILGOTINIB	4	MERTK
PACLITAXEL	4	MERTK
PAZOPANIB	4	MERTK
ERLOTINIB	4	MERTK
QUIZARTINIB	4	MERTK
MIDOSTAURIN	4	MERTK
CILOFEXOR	3	HSD17B13
ALVOCIDIB	3	DCLK1, MERTK
LAPAQUISTAT ACETATE	3	FDFT1
LINIFANIB	3	MERTK
ITACITINIB	3	MERTK
SURUFATINIB	3	MERTK

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 8.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
MERTK	443	Binding:442, Functional:1
DCLK1	150	Binding:149, Functional:1
CACNA2D1	47	Binding:45, ADMET:1, Toxicity:1
FDFT1	40	Binding:40
MTARC1	25	Binding:12, ADMET:11, Unclassified:2
HSD17B13	22	Binding:20, Functional:2
FARSB	8	Binding:8
MACROD2	4	Binding:2, Toxicity:2
NGF	4	Binding:4
SAMM50	1	Binding:1
CRACR2A	1	Binding:1
PTPRU	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ST8SIA1	2.4.99.8	alpha-N-acetylneuraminate alpha-2,8-sialyltransferase
MACROD2	3.1.1.106	O-acetyl-ADP-ribose deacetylase
FARSB	6.1.1.20	phenylalanine-tRNA ligase
MTARC1	1.16.98.B1, 1.7.2.1	, nitrite reductase (NO-forming)
DCLK1	2.7.11.1	non-specific serine/threonine protein kinase
FDFT1	2.5.1.21	squalene synthase
MERTK	2.7.10.1	receptor protein-tyrosine kinase
PTPRU	3.1.3.48	protein-tyrosine-phosphatase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
DCLK1	150
MERTK	443

Pharmacogenomics

Cohort genes with a PharmGKB record: 30; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
PREGABALIN	4	CACNA2D1
GABAPENTIN	4	CACNA2D1
NIMODIPINE	4	CACNA2D1
TACRINE	4	CACNA2D1
FEDRATINIB	4	DCLK1, MERTK
RUXOLITINIB	4	DCLK1
TOFACITINIB CITRATE	4	DCLK1
TOFACITINIB	4	DCLK1
NINTEDANIB	4	DCLK1, MERTK
SUNITINIB	4	DCLK1, MERTK
CRIZOTINIB	4	DCLK1, MERTK
AMIODARONE	4	FDFT1
AXITINIB	4	MERTK
SORAFENIB	4	MERTK
NERATINIB	4	MERTK
CABOZANTINIB	4	MERTK
VANDETANIB	4	MERTK
BOSUTINIB	4	MERTK
FILGOTINIB	4	MERTK
PACLITAXEL	4	MERTK
PAZOPANIB	4	MERTK
ERLOTINIB	4	MERTK
QUIZARTINIB	4	MERTK
MIDOSTAURIN	4	MERTK
CILOFEXOR	3	HSD17B13
ALVOCIDIB	3	DCLK1, MERTK
LAPAQUISTAT ACETATE	3	FDFT1
LINIFANIB	3	MERTK
ITACITINIB	3	MERTK
SURUFATINIB	3	MERTK

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	4	CACNA2D1, DCLK1, FDFT1, MERTK
B	Phased (≥1) drug, not yet approved	2	FARSB, HSD17B13
C	Druggable family + PDB, no drug	4	MACROD2, PALLD, MTARC1, PTPRU
D	Druggable family + AlphaFold only, no drug	4	ST8SIA1, ZP4, PKD1L1, PZP
E	Difficult family or no structure, no drug	16	RNF7, TM6SF2, TULP1, PARVB, PNPLA3, COL13A1, SAMM50, GLT8D2, DDX60L, CRACR2A (+6 more)

Undrugged target profiles

24 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
TM6SF2	0	HSD17B13
TULP1	0	MERTK
PNPLA3	0	HSD17B13
MTARC1	25	HSD17B13
RNF7	0	—
ST8SIA1	0	—
PARVB	0	—
ZP4	0	—
MACROD2	4	—
PALLD	0	—
PKD1L1	0	—
COL13A1	0	—
SAMM50	1	—
GLT8D2	0	—
DDX60L	0	—
CRACR2A	1	—
EHBP1L1	0	—
TEX36	0	—
FARP1	0	—
LTBP2	0	—
NGF	4	—
SERPINA1	0	—
PTPRU	1	—
PZP	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 542.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	345
PHASE4	65
PHASE3	42
PHASE2	42
PHASE1	18
PHASE2/PHASE3	17
PHASE1/PHASE2	10
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05147090	PHASE4	ACTIVE_NOT_RECRUITING	Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
NCT05737030	PHASE4	ACTIVE_NOT_RECRUITING	Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome
NCT06594783	PHASE4	RECRUITING	Carvedilol Plus EVL or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders
NCT06808074	PHASE4	RECRUITING	A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis
NCT06881628	PHASE4	RECRUITING	Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients
NCT07132515	PHASE4	RECRUITING	Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
NCT07322237	PHASE4	RECRUITING	DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
NCT07521332	PHASE4	RECRUITING	Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis
NCT00108355	PHASE4	COMPLETED	Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
NCT00179413	PHASE4	COMPLETED	Study of Long-term Peg Intron vs. Colchicine in Non-responders.
NCT00287664	PHASE4	SUSPENDED	Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin
NCT00347009	PHASE4	COMPLETED	Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis
NCT00359853	PHASE4	COMPLETED	Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
NCT00414713	PHASE4	UNKNOWN	Transfusion Requirements in Gastrointestinal (GI) Bleeding
NCT00450164	PHASE4	COMPLETED	Secondary Prophylaxis After Variceal Bleeding in Non-Responders
NCT00513201	PHASE4	COMPLETED	Lyspro Insulin vs Regular Insulin in Cirrhotic Patients
NCT00534677	PHASE4	COMPLETED	The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
NCT00570622	PHASE4	COMPLETED	Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis
NCT00570973	PHASE4	COMPLETED	Band Ligation Versus Transjugular Intrahepatic Portosystemic Stent Shunt (TIPS) in Cirrhotics With Recurrent Variceal Bleeding Non Responding to Medical Therapy
NCT00596414	PHASE4	COMPLETED	Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial
NCT00741663	PHASE4	COMPLETED	Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)
NCT00760032	PHASE4	WITHDRAWN	Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients
NCT00761098	PHASE4	UNKNOWN	Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)
NCT00906139	PHASE4	UNKNOWN	Propofol and Fentanyl Versus Midazolam and Fentanyl for Endoscopy Sedation in Cirrhotic Patients
NCT00921349	PHASE4	COMPLETED	A Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis
NCT00965900	PHASE4	UNKNOWN	Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding
NCT00966082	PHASE4	UNKNOWN	EBL Versus EBL and Propranolol for the Prevention of Variceal Rebleeding in Pts With Previous Variceal Treatment
NCT00966121	PHASE4	UNKNOWN	Endoscopic Band Ligation (EBL) Versus Endoscopic Band Ligation and Propranolol for the Prevention of Variceal Rebleeding
NCT00968695	PHASE4	COMPLETED	Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.
NCT01292304	PHASE4	COMPLETED	Tolvaptan for Ascites in Cirrhotic Patients
NCT01530711	PHASE4	UNKNOWN	Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response
NCT01686698	PHASE4	COMPLETED	Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis
NCT01722578	PHASE4	COMPLETED	L-ornithine L-aspartate in Overt Hepatic Encephalopathy
NCT01820026	PHASE4	UNKNOWN	Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis
NCT01842581	PHASE4	COMPLETED	The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
NCT01847651	PHASE4	COMPLETED	Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate
NCT01893541	PHASE4	COMPLETED	PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES?
NCT02074280	PHASE4	UNKNOWN	Rifaximin Predicts the Complications of Decompensated Cirrhosis
NCT02190357	PHASE4	UNKNOWN	Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial
NCT02238444	PHASE4	UNKNOWN	Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PROPRANOLOL	4	24
ALBUMIN HUMAN	4	12
CARVEDILOL	4	8
TERLIPRESSIN	4	7
TOLVAPTAN	4	7
LACTULOSE	4	6
MIDODRINE	4	5
RIFAXIMIN	4	5
SOFOSBUVIR	4	4
DACLATASVIR	4	3
DIPYRIDAMOLE	4	3
NORFLOXACIN	4	3
PRAZOSIN	4	3
SPIRONOLACTONE	4	3
WARFARIN	4	3
ADEFOVIR DIPIVOXIL	4	2
ALLOPURINOL	4	2
APIXABAN	4	2
BACLOFEN	4	2
BOCEPREVIR	4	2
CEFOTIAM	4	2
COSYNTROPIN	4	2
EMPAGLIFLOZIN	4	2
EPTACOG ALFA (ACTIVATED)	4	2
FUROSEMIDE	4	2
LEDIPASVIR	4	2
MIDAZOLAM	4	2
NADOLOL	4	2
OCTREOTIDE	4	2
OMBITASVIR	4	2